Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity

Supplementary Material

Supplementary Figure 1: BPTES inhibits DLBCL, NHL and Burkitt's lymphoma cell growth as assessed through cell number. Cell number was assessed through cell number cell 72 hr post BPTES treatment. Data representative of 3 independent experiments.

Supplementary Table 1: MYC status of the DLBLC, NHL and Burkitt’s lymphoma cell line panel. (ABC: activated B-cell. GBC: germinal center B-cell).

| Cell Line     | Type      | slg    | MYC status           |
|---------------|-----------|--------|----------------------|
| HBL-1         | ABC       | IgM    |                       |
| HT            | GCB       | IgM    |                       |
| KARPAS-422    | GCB       | IgMG   |                       |
| TMD8          | ABC       | IgM    |                       |
| WSU-DLCL-2    | GCB       | IgG    |                       |
| Raji          | translocation |       |                       |
| Su-DHL-10     | GCB       | IgG    | translocation (8;14) (q24;q32) |
